Assessment of the bacteriological effect of combined treatment with rifadin, sulfamethoxypyrazine, and isoniazide in lepromatous leprosy.
D004359:Drug Therapy, Combination; D006801:Humans; D007538:Isoniazid / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D008826:Microbial Sensitivity Tests; D009130:Muscle, Smooth; D009166:Mycobacterium leprae / Q000187:drug effects; D011719:Pyrazines / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use*; D012867:Skin; D013424:Sulfanilamides / Q000627:therapeutic use*; D013997:Time Factors
D011719:Pyrazines; D013424:Sulfanilamides; D007538:Isoniazid; D012293:Rifampin